Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.66 |
| ▸ | FNTB | P49356 | 8/20 | 0.66 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544520 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL13093207 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL9510846 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051273 | 0.97 | FNTA (0.63) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051274 | 0.96 | FNTA (0.62) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30209468 | 0.96 | FNTA (0.62) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051169 | 0.94 | FNTA (0.63) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051757 | 0.94 | FNTA (0.59) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL6241495 | 0.92 | LTA4H (0.60) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051749 | 0.92 | FNTA (0.61) | FNTAFNTBPGGT1BLTA4HKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1117760-C | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2003-08-13 | — | — | CN | claimed |
| CN-1100426-A | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 1995-03-22 | — | — | CN | claimed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| CN-115389756-B | Detection kit for predicting risk of atrial fibrillation and application thereof | 首都医科大学附属北京安贞医院 | 2023-02-17 | — | — | CN | disclosed |
| CN-115389756-A | Detection kit for predicting risk of atrial fibrillation and application thereof | 首都医科大学附属北京安贞医院 | 2022-11-25 | — | — | CN | disclosed |
| EP-3954991-A2 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | Laboratory Corporation of America Holdings (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3151665-B1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORP AMERICA HOLDINGS (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3219324-B1 | APPLICATION OF DIPEPTIDE AS ACE ENZYME ACTIVITY INHIBITOR | WITHYOU BIOTECHNOLOGY CO LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| US-20160091481-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2016-03-31 | — | — | US | disclosed |
| US-9176113-B1 | Methods and systems for determining autism spectrum disorder risk | SYNAPDX CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150293072-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2015-10-15 | — | — | US | disclosed |
| US-20150294081-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2015-10-15 | — | — | US | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| JP-2008297208-A | ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR | KYOWA HAKKO KIRIN CO LTD | 2008-12-11 | — | — | JP | disclosed |
| EP-0331404-A2 | Method for producing tropane alkaloid | SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) | 1989-09-06 | — | — | EP | disclosed |